Dacomitinib vs Erlotinib Improves PFS in Advanced NSCLC

Share this content:
(ChemotherapyAdvisor) – Dacomitinib, an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, demonstrated significantly improved progression-free survival (PFS) when compared with erlotinib in patients with advanced non-small cell lung cancer (NSCLC), results of a randomized phase 2 study published in the Journal of Clinical Oncology online July 2 have found.

The global open-label trial, the first to compare an irreversible pan-HER tyrosine kinase inhibitor (TKI) with a reversible EGFR-selective TKI, randomly assigned 188 patients with NSCLC and no prior HER-directed therapy and one or two prior chemotherapy regimens to dacomitinib 45mg/day or erlotinib 150mg/day.

Median PFS, the primary end point, was 2.86 months in the dacomitinib arm and 1.91 months in the erlotinib arm (HR 0.66 [95% CI, 0.47–0.91; two-sided P=0.012). Patients with KRAS wild-type tumors had a median PFS of 3.71 when treated with dacomitinib vs 1.91 months for erlotinib (HR 0.55 [95% CI, 0.35–0.85]; two-sided P=0.006); for those with KRAS wild-type/EGFR wild-type tumors, median PFS was 2.21 months vs 1.84 months, respectively (HR 0.61 [95% CI, 0.37–0.99]; two-sided P=0.043).

Median overall survival was 9.53 months in the dacomitinib arm and 7.44 months in the erlotinib arm (HR 0.80 [95% CI, 0.56–1.13]; two-sided P=0.205).

Consistent with the expected toxicities of EGFR TKIs, skin effects and diarrhea were the prominent adverse events, they reported, which were predominantly grade 1 to 2, and more frequent with dacomitinib.

The investigators noted that PFS benefit with dacomitinib “was observed in most clinical and molecular subsets, notably KRAS wild-type/EGFR any status, KRAS wild-type/EGFR wild-type, and EGFR mutants.”

An ongoing phase 3 study (ARCHER 1009 [Advanced Research for Cancer Targeted Pan-HER Therapy]) will confirm the results of this study for the treatment of second- and third-line therapy in patients with advanced NSCLC. “This study includes coprimary end points (PFS in all patients and in patients with wild type KRAS/EGFR any status) to allow evaluation of dacomitinib in an unselected population and to prospectively evaluate the relationship between KRAS molecular status and clinical outcome,” they wrote.

Abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs